New York, NY (PRWEB) January 27, 2014
Thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) that allege the blood thinners caused patients to suffer serious, and even deadly, episodes of internal bleeding, are moving forward in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to an Order dated January 23, 2014, Judge David Herndon has selected four specific Pradaxa lawsuits for the proceeding’s first bellwether trials, which are scheduled to begin in August 2014. The first two trials will involve wrongful death claims, while the third and fourth Pradaxa trials will involve cases that allege the drug caused plaintiffs to suffer gastrointestinal hemorrhaging. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“We have heard from a number of individuals who allegedly experienced serious episodes of Pradaxa bleeding. We are pleased to see these cases moving forward, and look forward to the start of bellwether trials later this year,” says Bernstein Liebhard LLP, nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to individuals who may have been harmed by this blood thinner.
According to court documents, more than 2,100 claims have been filed in the Southern District of Illinois on behalf of alleged victims of Pradaxa bleeding. All of the lawsuits claim that Boehringer Ingelheim failed to provide adequate warnings about the drug’s association with internal bleeding, including the fact that there currently exists no readily-available reversal agent to treat Pradaxa bleeding.
According to Pradaxa lawsuits, all blood thinners carry a risk of internal bleeding, but Pradaxa was touted as being safer than warfarin, a blood thinning drug that has been on the market for decades. The lawsuits further point out that while hemorrhaging associated with warfarin can be stopped via the administration of vitamin K, there is no antidote to treat Pradaxa bleeding.
In December, the U.S. Food & Drug Administration (FDA) announced that it would begin a large-scale study of Pradaxa bleeding rates in order to compare “selected safety outcomes in adults with atrial fibrillation who are new users of dabigatran or warfarin.”
In April, the Institute for Safe Medicine Practices (ISMP) reported that Pradaxa had been named in more than 3,200 FDA adverse event reports in 2012, the most of any drug monitored by the agency. Of those, more than 580 involved a patient death. By contrast, warfarin was named in only 861 incident reports, including 56 deaths.*
Individuals who allegedly suffered serious internal bleeding, including cerebral or gastrointestinal hemorrhage, due to Pradaxa may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to schedule a free, no obligation case review.
*ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com